ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results
of Operations
The following discussion and analysis should be read together with our unaudited condensed
consolidated financial statements and related notes thereto set forth in this Quarterly Report on Form 10-Q as well as our Annual
Report on Form 10-K for the year ended December 31, 2019.
This Form 10-Q contains “forward-looking statements” that indicate certain
risks and uncertainties, many of which are beyond our control. Actual results could differ materially and adversely from those
anticipated in such forward-looking statements as a result of certain factors, including those set forth below and elsewhere in
this report. Important factors that may cause actual results to differ from projections include:
|
·
|
We may not be able to continue operating without additional financing;
|
|
·
|
Current negative operating cash flows;
|
|
·
|
The terms of any further financing, which may be highly dilutive and may include onerous terms;
|
|
·
|
Significant debt repayments due between June and September 2020, which the Company will likely need to
extend or restructure, with no assurance that this will be possible;
|
|
·
|
Risks related to the 2019 merger with Helomics including; 1) significant goodwill could result in further impairment; 2) possible failure to realize anticipated benefits of the merger; 3) costs associated with the merger may be higher than expected; 4) the merger may result in the disruption of our existing businesses; and 5) distraction of management and diversion of resources;
|
|
·
|
Risks related to our partnerships with other companies, including the need to negotiate the definitive agreements; possible failure to realize anticipated benefits of these partnerships; and costs of providing funding to our partner companies, which may never be repaid or provide anticipated returns;
|
|
·
|
Risks related to the transaction with Quantitative Medicine including:
1) completion of the transaction; 2) possible failure to realize anticipated benefits of the acquisition; 3) costs associated with
the acquisition may be higher than expected; 4) the acquisition may result in the disruption of our existing businesses; and 5)
distraction of management and diversion of resources;
|
|
·
|
Risks related to the transaction with InventaBioTech for the asset purchase from Soluble Therapeutics
and BioDtech including: 1) completion of the transaction; 2) possible failure to realize anticipated benefits of the transaction;
3) costs associated with the transaction may be higher than expected; 4) the transaction may result in the disruption of our existing
businesses; and 5) distraction of management and diversion of resources;;
|
|
·
|
Risk that we will be unable to protect our intellectual property or claims that we are infringing on others’ intellectual property;
|
|
·
|
The impact of competition;
|
|
·
|
Acquisition and maintenance of any necessary regulatory clearances applicable to applications of our technology;
|
|
·
|
Inability to attract or retain qualified senior management personnel, including sales and marketing personnel;
|
|
·
|
Risk that we never become profitable if our product is not accepted by potential customers;
|
|
·
|
Possible impact of government regulation and scrutiny;
|
|
·
|
Unexpected costs and operating deficits, and lower than expected sales and revenues, if any;
|
|
·
|
Adverse results of any legal proceedings;
|
|
·
|
The volatility of our operating results and financial condition, and,
|
|
·
|
Risk that our business and operations will continue to be materially and adversely affected by the COVID-19
pandemic, which has (1) impacted a significant supplier; (2) resulted in a reduction in on-site staff at several of our facilities
and in delayed production and less efficiency; and (3) impacted our sales efforts, accounts receivable, and terms demanded by suppliers;
and
|
|
·
|
Other specific risks that may be alluded to in this report.
|
All statements, other than statements of historical facts, included in this report regarding
our growth strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans,
and objectives of management are forward-looking statements. When used in this report, the words “will,” “may,”
“believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,”
“plan,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking
statements contain such identifying words. All forward-looking statements speak only as of the date of this report. We
do not undertake any obligation to update any forward-looking statements or other information contained herein. Potential
investors should not place undue reliance on these forward-looking statements. Although we believe that our plans, intentions,
and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure potential
investors that these plans, intentions or expectations will be achieved. We disclose important factors that could cause actual
results to differ materially from expectations in the “Risk Factors” section and elsewhere in our Annual Report on
Form 10-K for the year ended December 31, 2019 and in item 1A of Part II below. These cautionary statements qualify all forward-looking
statements attributable to us or persons acting on our behalf.
Information regarding market and industry statistics contained in this report is included
based on information available to us that we believe is accurate. It is generally based on academic and other publications
that are not produced for purposes of securities offerings or economic analysis. We have not reviewed or included data from
all sources, and we cannot assure potential investors of the accuracy or completeness of the data included in this report. Forecasts
and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties
accompanying any estimates of future market size, revenue, and market acceptance of products and services. We have no obligation
to update forward-looking information to reflect actual results or changes in assumptions or other factors that could affect those
statements.
Overview
We operate in two primary business areas: first, application of artificial intelligence
(“AI”) in our precision medicine business, to provide AI-driven predictive models of tumor drug response to improve
clinical outcomes for patients and to assist pharmaceutical, diagnostic, and biotech industries in the development of new personalized
drugs and diagnostics; and second, production of the United States Food and Drug Administration (“FDA”)-cleared STREAMWAY®
System for automated, direct-to-drain medical fluid disposal and associated products.
We have three operating segments: domestic, international, and Helomics. Domestic and
international consist of the STREAMWAY System product sales. The Helomics segment consists of clinical testing and contract research.
Our TumorGenesis subsidiary is included within corporate. Going forward, we have determined that we will focus our resources on
the Helomics segment and our primary mission of applying AI to precision medicine and drug discovery.
Precision Medicine Business
Our precision medicine business, conducted in our Helomics division, is committed to
improving the effectiveness of cancer therapy using our proprietary, multi-omic tumor profiling platform, one-of-a-kind database
of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Helomics’ mission is to improve clinical outcomes for patients by partnering with
pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace.
In addition to our proprietary patient-derived (“PDx”) tumor profiling platform for oncology, Helomics offers: 1) data
and AI driven contract research organization (“CRO”) services for clinical and translational research that leverage
PDx tumor models, 2) a wide range of multi-omics assays (genomics, proteomics, and biochemical), and 3) AI driven predictive models
to drive the discovery of targeted therapies.
Contract Research Organization (CRO) and AI-Driven Business
We believe leveraging our unique, historical database of the drug responses of over 149,000
patient tumors to build AI and data-driven multi-omic predictive models of tumor drug response and outcome will provide actionable
insights critical to both new drug development and individualizing patient treatment. Our large historical database of tumors and
related data, plus our ability to obtain the associated patient outcome data is a significant competitive advantage. Cancer treatments
require at least 5 years of testing to provide sufficient information on progression-free survival rates. While competitors must
wait for this data, we can leverage it today. These AI-driven predictive models, coupled with the PDx platform will create a unique
service to drive revenue generating projects with pharma, diagnostic and biotech companies in areas such as biomarker discovery,
drug screening, drug repurposing, and clinical trials. The AI-driven models will, once validated, also provide clinical decision
support to help oncologists individualize treatment.
Our CRO/AI business is committed to improving the process of targeted therapy discovery.
Our proprietary, TruTumor multi-omic PDx profiling and AI platform coupled to our vast multi-omic database of biochemical and clinical
information on patients with cancer, uses deep learning to understand the association between the mutational profile of a patient’s
tumor and the drug response profile of the tumor that is grown in the lab. This approach is used to build an AI-driven predictive
model that offers actionable insights of which mutations in the tumor are associated with drugs to which the tumor is sensitive
and which will lead to the optimal outcome for the patient.
Our CRO services business applies these AI-driven predictive models coupled with our
unique proprietary TruTumor PDx model to address a range of needs from discovery through clinical and translational research, to
clinical trials and diagnostic development and validation as noted below:
Research
Development
|
•
|
Patient enrichment & selection for trials
|
|
•
|
Clinical trial optimization
|
Clinical Decision Support
Clinical Testing
Via our Helomics subsidiary, we offer a group of clinically relevant, cancer-related
tumor profiling and biomarker tests for gynecological cancers that determine how likely the patient is to respond to various types
of chemotherapy and which therapies might be indicated by relevant tumor biomarkers.
Clinical testing is comprised of ChemoFx and BioSpeciFx tests. The ChemoFx test determines
how a patient’s tumor specimen responds to a panel of various chemotherapy drugs, while the BioSpeciFx test evaluates the
expression of a specific genes, or biomarkers, in the patient’s tumor. Our proprietary TruTumor™ PDx tumor platform
provides us with the ability to work with actual live tumor cells to study the unique biology of the patient’s tumor in order
to understand how the patient responds to treatment.
Skyline Medical – The STREAMWAY System
Sold through our subsidiary, Skyline Medical, Inc (“Skyline Medical”),
the STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids
found in the healthcare environment. Antiquated manual fluid handling methods that require hand carrying and emptying filled
fluid canisters present both an exposure risk and potential liability. Skyline Medical’s STREAMWAY System fully
automates the collection, measurement, and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals
and surgical centers; 2) improve compliance with the Occupational Safety and Health Administration and other regulatory
agency safety guidelines; 3) improve efficiency in the operating room and radiology and endoscopy departments, thereby
leading to greater profitability; and 4) provide greater environmental stewardship by helping to eliminate the approximately
50 million potentially disease-infected canisters that go into landfills each year in the United States.
In December 2019, we announced that we had received indications of interest from several
parties for the possible acquisition of our Skyline Medical division, and we reaffirmed that we are focusing our resources on our
precision medicine business. We continue to operate the Skyline Medical business with a focus on maximizing our strategic opportunities
with respect to this division.
STREAMWAY System Product Sales
Our domestic and international segments consist primarily of sales of the STREAMWAY System,
as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. We manufacture an environmentally
conscious system for the collection and disposal of infectious fluids resulting from surgical and other medical procedures. We
have been granted patents for the STREAMWAY System in the United States, Canada, and Europe. We distribute our products to medical
facilities where bodily and irrigation fluids produced during medical procedures must be contained, measured, documented, and disposed.
Our products minimize the exposure potential to the healthcare workers who handle such fluids. In addition to simplifying the handling
of these fluids, our goal is to create products that dramatically reduce staff exposure without significant changes to established
operative procedures, historically a major industry stumbling block to innovation and product introduction.
We sell our medical device products directly to hospitals and other medical facilities
using employed sales representatives, independent contractors and distributors.
Our subsidiary, TumorGenesis, is pursuing a new rapid approach to growing tumors in the
laboratory, which essentially “fools” the cancer cells into thinking they are still growing inside the patient. We
have also announced a proposed joint venture with GLG Pharma focused on using their combined technologies to bring personalized
medicines and testing to ovarian and breast cancer patients, especially those who present with ascites fluid (over one-third of
patients).
Capital Requirements
Since inception, we have been unprofitable. We incurred net losses of $4,529,317 and
$3,293,184 for the three-month periods ended March 31, 2020 and 2019, respectively. As of March 31, 2020, and December 31, 2019,
we had an accumulated deficit of $87,028,028 and $82,498,711, respectively.
We have never generated sufficient revenues to fund our capital requirements. From 2009
through 2018, we built the Skyline Medical business, building a national sales network and international sales. However, the Skyline
Medical business has never reached profitability. In 2017, we determined to diversify our business by investing in ventures in
the precision medicine business, including making significant loans and investments in early stage companies. These activities
led to the acquisition of Helomics in April 2019, which has accelerated our capital needs further. We have funded our operations
through a variety of debt and equity instruments. See “Liquidity and Capital Resources – Plan of Financing; Going Concern
Qualification” and “Liquidity and Capital Resources – Financing Transactions” below.
Our future cash requirements and the adequacy of available funds depend on our ability
to generate revenues from our Helomics segment; to continue to sell our Skyline Medical products and attempt to reach profitability
in the Skyline Medical business and the availability of future financing to fulfill our business plans. See “Plan of Financing;
Going Concern Qualification” below.
Our limited history of operations, especially in our precision medicine business, and
our change in the emphasis of our business, makes prediction of future operating results difficult. We believe that period to period
comparisons of our operating results should not be relied on as predictive of our future results.
Results of Operations
Comparison of three-month periods ended March 31, 2020 and March 31, 2019
|
|
Three Months Ended
March 31, 2020
|
|
Three Months Ended
March 31, 2019
|
|
Difference
|
Revenue
|
|
$
|
294,943
|
|
|
$
|
255,241
|
|
|
$
|
39,702
|
|
Cost of goods sold
|
|
|
92,657
|
|
|
|
73,717
|
|
|
|
18,940
|
|
General and administrative expense
|
|
|
2,828,476
|
|
|
|
1,497,945
|
|
|
|
1,330,531
|
|
Operations expense
|
|
|
548,753
|
|
|
|
466,566
|
|
|
|
82,187
|
|
Sales and marketing expense
|
|
|
264,409
|
|
|
|
554,216
|
|
|
|
(289,807
|
)
|
Revenue. We recorded revenue of $294,943 and $255,241 in the three-month periods
ended March 31, 2020 and 2019, respectively. All revenue was derived from the Skyline Medical business except for $15,130
in Helomics revenues in the 2020 period. We sold 5 and 7 STREAMWAY System units in each of 2020 and 2019 periods, respectively.
Cost of sales. Cost of sales was $92,657 and $73,717 in the three-month
periods ended March 31, 2020 and March 31, 2019, respectively. The gross profit margin was approximately 69% in the three
months ended March 31, 2020, compared to 71% in the three months ended March 31, 2019. Our margins decreased in the first
quarter of 2020 primarily due to Helomics costs surpassing the revenue earned in the same period. Exclusive of Helomics,
gross profit margin related to the Skyline Medical business in the first quarter of 2020 increased to 77% in the three months
ended March 31, 2020.
General and Administrative expense. General and administrative (“G&A”)
expense primarily consists of management salaries, professional fees, consulting fees, travel expense, administrative fees and
general office expenses.
G&A expense expenses increased by $1,330,531 to $2,828,476 for the
three months ended March 31, 2020 compared to $1,497,945 in the 2019 period. The increase was primarily due to additional costs
related to the Helomics business. As a result of the combined company, salaries, stock-based compensation, rent and depreciation,
and amortization all increased substantially.
Operations expense. Operations expense primarily consists of expenses related
to product development and prototyping and testing in our current stage.
Operations expense increased by $82,187 to $548,753 in the three months ended March 31,
2020 compared to $466,566 in the comparable period in 2019. The increase was primarily due to higher payroll costs related to the
addition of Helomics, partially offset by a reduction in research and development costs.
Sales and marketing expense. Sales and marketing expense consists of expenses
required to sell products through independent reps, attendance at trade shows, product literature and other sales and marketing
activities.
Sales and marketing expense decreased by $289,807 to $264,409 in the three months ended
March 31, 2020 compared to $554,216 in the comparable period in 2019. Such expenses related almost exclusively to the Skyline Medical
business. The decrease in 2020 was a direct result of the strategic decision focus on the precision medicine business and reduce
the emphasis on expenditures in the Skyline Medical business. These factors decreased our expenses for public relations and decreases
in salary and travel costs for sales staff.
Impact of minority investment on net loss. The net loss for the three months ended
March 31, 2019 includes a loss on equity method investment of $439,637. The 2019 loss represented a portion of Helomics’
net loss from continuing operations prior to the merger on April 4, 2019 and resulted from our ownership of 25% of Helomics’
capital stock before the merger. Commencing with the merger effective April 4, 2019, we own 100% of the Helomics business, which
is included in the consolidated financial statements.
Other income. We earned other income of $27,110 in the three months ended March
31, 2020 compared to $53,432 in the comparable period in 2019. Other income was comprised of net unrealized gains related to the
derivative liabilities and interest and dividend income.
Other expense. We incurred other expense of $1,117,075 in the three months ended
March 31, 2020 compared to $569,776 in the comparable period in 2019. Other expense consisted primarily of interest expense, payment
penalties, amortization of original issue discounts, and loss on debt extinguishment related to our notes payable.
Liquidity and Capital Resources
Cash Flows
Net cash used in operating activities was $2,972,981 and $2,048,653 for the three months
ended March 31, 2020 and March 31, 2019, respectively. Cash used in operating activities increased in the 2020 period primarily
because of the increase in total operating expense and the additional costs related to the Helomics business.
Cash flows used in investing activities were $32,510 and $624,651 for the three months
ended March 31, 2020 and March 31, 2019, respectively. Cash used in the three months ended March 31, 2020 was for the acquisition
of intangible assets. Cash used in the three months ended March 31, 2019 was for cash advances made to Helomics prior to the acquisition
but was partially offset by cash received from Helomics on the acquisition date.
Net cash provided by financing activities was $5,910,903 and $3,635,882
for the three months ended March 31, 2020 and March 31, 2019, respectively. The cash provided in the three months ended March 31,
2020 were primarily due to proceeds from debt issuance, proceeds from issuance of common stock and prefunded warrants related to
a private placement offering, and proceeds from the issuance common stock pursuant to the equity line agreement.
Liquidity, Plan of Financing, and Going Concern Qualification
Since our inception, we have incurred significant losses, and our accumulated deficit
was $87,028,028 as of March 31, 2020. We have not achieved profitability and anticipate that we will continue to incur net losses
at least through the remainder of 2020. Our operations from inception have been funded with private placements of convertible
debt securities and equity securities, public offerings, and loan agreements.
During the first quarter of 2020, we entered into short-term borrowings with an investor
for cash proceeds of $1,020,000. On October 24, 2019, we entered into an equity purchase agreement with an investor, providing
for an equity financing facility. From January 1, 2020 through March 12, 2020, we issued an aggregate 943,000 shares of common
stock valued at $1,869,899. The Company used a portion of the net proceeds to repay $821,916 of the short-term borrowings. In February
2020, we entered into a sale of a secured promissory note to a private investor for $1,450,000 with total net proceeds of $1,200,000,
$800,000 of which was received prior to March 31, 2020. In March 2020, we received gross proceeds of $3,498,612 from the sale of
common stock, common stock equivalents, and warrants. In May 2020, we received gross proceeds of $2,200,001 from a registered direct
offering of common stock and a concurrent private placement of warrants. The Company used approximately $482,525 of the net proceeds
from the offering to repay certain indebtedness to Oasis Capital, LLC and agreed to use the remaining net proceeds from the offering
for general corporate purposes.
As a result of the exchange of the notes issued to Carl Schwartz
and the draw on the third tranche of the Promissory Notes 2020 described under “Financing Transactions” below, the
following are the mandatory repayment dates of our indebtedness (unless portions of certain notes are earlier converted or unless
notes are further extended) (amounts shown include assumed interest accruing through the due date): (1) secured notes due on June
28, 2020, with a total amount payable on that date of $3,753,645 (including current principal and assumed interest); (2) a secured
notes due on August 5, 2020 and October 5, 2020 with a total amount payable of $1,806,506, (including current principal, assumed
interest and a 20% premium payable upon repayment) and (3) notes due between August 12, 2020 and September 11, 2020 with a total
amount payable on that date of $772,961 (including current principal and assumed interest).
As a result of our capital needs for operations and debt repayment, we need to raise
significant capital. There is no assurance that we will be successful in raising sufficient capital. The terms of any such financing
will be dilutive to our stockholders. We may also acquire technologies or companies by issuing stock or other equity securities
in addition to payment of cash, which may have the result of diluting the investment of our stockholders.
We will attempt to raise these funds through equity or debt financing. We will attempt
to raise funds from other sources that may include public offerings, private placements, alternative offerings, or other means.
If we are successful in securing adequate funding, we plan to make significant capital or equipment investments, and we will also
continue to make human resource additions in Helomics. If such financing or adequate funds from operations are not available, we
will be forced to limit our business activities, which will have a material adverse effect on our results of operations and financial
condition.
As a result of the above factors, we have concluded that there
is substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements have been
prepared assuming we will continue as a going concern. Furthermore, our former independent registered public accounting firm has
indicated in their audit opinion, contained in our consolidated financial statements included in our Annual Report on Form 10-K
for the year ended December 31, 2019, that there is substantial doubt about our ability to continue as a going concern.
Financing Transactions
We have funded our operations through a combination of debt and
equity instruments including short term borrowings, and a variety of debt and equity offerings.
February 2020 Convertible Note
On February 5, 2020, we entered into a securities purchase agreement with an investor,
pursuant to which we issued a convertible promissory note to the investor in the principal amount of $1,450,000 in exchange for
cash proceeds of $1,200,000. $240,000 of the note’s principal represents an original issue discount (“OID”) and
the remaining $10,000 represents a credit for the investor’s transaction expenses. We granted to the investor a security
interest in our assets to secure repayment of the note. The principal amount of the note accrues interest at a rate of 8% per annum
(with six months of interest guaranteed). Unless previously converted, the note will mature and become due and payable on August
5, 2020. We will incur a 20% repayment charge in connection with any repayment of principal under the note. Subject to certain
limitations, the outstanding principal amount of the note and interest thereon are convertible at the election of the investor
into shares of our common stock at a conversion price equal to $2.589. Advances under the note will be made in three tranches.
Net proceeds of $400,000 were received for the first, second and third tranches on February 5, 2020, March 5, 2020 and April 5,
2020, respectively. We issued to the investor five-year warrants to purchase 94,631 and 92,700 shares of our common stock at the
closing of the first and second tranches, respectively, and issued warrants to purchase 92,700 shares at the closing of the third
tranche. The warrants are exercisable beginning on the sixth month anniversary of the issuance date at an exercise price equal
$2.992 per share. As additional consideration for the investment, we issued 46,875 shares of our common stock as inducement shares
to the investor at the closing of the first tranche.
March 2020 Private Placement of Common Stock and Warrants
On March 19, 2020, we sold and issued (1) 260,000 shares of common
stock, at a sale price of $2.121 per share; (2) prefunded warrants to acquire 1,390,166 shares of common stock, sold at $2.12 per
share and exercisable at an exercise price of $0.001 per share; (3) warrants to acquire 1,650,166 shares of common stock at $1.88
per share, exercisable immediately and terminating five and one-half years after the date of issuance; and (4) warrants to acquire
1,650,166 shares of common stock at $1.88 per share, exercisable immediately and terminating two years after the date of issuance.
The gross proceeds were $3,498,612. In the securities purchase agreement with the investors dated March 13, 2020, until 90 days
after the initial registration statement required by the Registration Rights Agreement is declared effective by the SEC, neither
us nor any of our subsidiaries will issue, enter into any agreement to issue or announce the issuance or proposed issuance of any
shares of common stock or common stock equivalents. Notwithstanding the foregoing, if, at any time following 30 days after the
effective date of such registration statement, the last closing sale price for the common stock on the Nasdaq Capital Market is
at least $6.30 (subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar
transactions of the common stock that occur after the date of the Purchase Agreement) for three consecutive trading days, then
these issuance restrictions no longer apply.
March 2020 Amendments to and Extensions of Promissory Notes
On March 19, 2020, we entered into a third amendment to the Amended and Restated Senior
Secured Promissory Note dated September 28, 2018 and amended and restated as of February 7, 2019 issued to L2 Capital, LLC (as
amended by that certain First Amendment dated September 27, 2019 and that certain Second Amendment dated December 12, 2019, the
“L2 Note”). Under the third amendment, the maturity date of the L2 Note was extended from March 28, 2020 to June 28,
2020.
On March 19, 2020, we entered into an amendment to the Senior Secured Promissory Note
dated September 27, 2019 issued to Oasis Capital, LLC (the “Oasis Note”). Under the amendment, the maturity date of
the Oasis Note was extended from March 27, 2020 to June 27, 2020. In exchange for such extension, the outstanding principal amount
of the Oasis Note was increased by $300,000, such that, as of the effective date of the amendment, the outstanding principal amount
owed under the Oasis Note was $980,833. Under the amendment, through March 26, 2020, the holder waived its rights under the Oasis
Note to have the Oasis Note repaid from the proceeds of any financing consummated by us. In exchange for such waiver, we issued
30,000 shares of common stock to the holder.
April 2020 Paycheck Protection Program
On April 20, 2020, the Company entered into a promissory note with
Park State Bank, which provides for an unsecured loan of $541,867 pursuant to the Paycheck Protection Program (the “PPP”)
under the Coronavirus Aid, Relief, and Economic Security Act and applicable regulations (the “CARES Act”). The promissory
note has a term of 2 years with a 1% per annum interest rate. Payments are deferred for 6 months from the date of the promissory
note and the Company can apply for forgiveness of all or a portion of the promissory note after 60 days.
Pursuant to the terms of the PPP, the promissory note, or a
portion thereof, may be forgiven if proceeds are used for qualifying expenses as described in the CARES Act, such as payroll costs,
costs used to continue group health care benefits, mortgage interest payments, rent and utilities. The Company intends to use
all proceeds for qualifying expenses. The terms of the promissory note, including eligibility and forgiveness, may be subject
to further requirements in regulations and guidance adopted by the Small Business Administration.
May 2020 Registered Direct Offering of Common Stock and Concurrent
Private Placement of Warrants
During May 2020, the Company entered into a securities purchase
agreement with certain accredited investors for a registered direct offering of 1,396,826 shares of common stock, par value $0.01
per share. The shares were registered pursuant to the Company’s registration statement on Form S-3 (File No. 333-234073)
(the “Shelf Registration Statement”) which was declared effective by the SEC on December 20, 2019. In a concurrent
private placement, the Company also issued such investors warrants to purchase up to an aggregate of 1,396,826 shares of our common
stock. The Warrants were not registered pursuant to the Shelf Registration Statement. The Company agreed that, as soon as practicable,
it shall file a registration statement providing for the resale of the shares of our common stock issuable upon the exercise of
the warrants and to use commercially reasonable efforts to cause the registration statement to become effective. The Shares and
the Warrants were sold at a combined offering price of $1.575 per Share and associated Warrant. Each Warrant is exercisable immediately
upon issuance at an exercise price of $1.45 per share and will expire five and one-half years from the issue date. The sale of
the offering shares and associated warrants resulted in gross proceeds of $2,200,001 and net proceeds of $1,930,101 after deducting
the placement agent fees and estimated offering expenses payable by the Company. The Company used approximately $482,525 of the
net proceeds from the offering to repay certain indebtedness and agreed to use the remaining net proceeds from the offering for
general corporate purposes. The offering closed on May 8, 2020.
Off-Balance Sheet Arrangements
We have not engaged in any off-balance sheet activities as defined in Item 303(a)(4)
of Regulation S-K.
Accounting Standards and Recent Accounting Developments
See Note 1 - Summary of Significant Accounting Policies to the
unaudited, Condensed Consolidated Financial Statements of this Quarterly Report on Form 10-Q for a discussion of recent accounting
developments.